Results 11 to 20 of about 22,145 (200)

NKG2D+CD4+ T Cells Kill Regulatory T Cells in a NKG2D-NKG2D Ligand- Dependent Manner in Systemic Lupus Erythematosus [PDF]

Scientific Reports, 2017
Systemic lupus erythematosus (SLE) features a decreased pool of CD4+CD25+Foxp3+ T regulatory (Treg) cells. We had previously observed NKG2D+CD4+ T cell expansion in contrast to a decreased pool of Treg cells in SLE patients, but whether NKG2D+CD4+ T ...
Di Yang, Zhiqiang Tian, Mengjie Zhang, Weibing Yang, Jun Tang, Yuzhang Wu, Bing Ni   +6 more
doaj   +3 more sources

A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer. [PDF]

Adv Sci (Weinh)
A dual‐transmembrane Bicephali CAR‐T platform simultaneously targets CD276 and NKG2D ligands to address antigen heterogeneity in non‐small cell lung cancer. By improving immune synapse formation, mitochondrial fitness, antioxidant capacity, and stem‐like persistence, this design enhances durable tumor control and provides a versatile strategy to ...
Wang L, Zhang Y, Peng S, Hou C, Guo H, Zhou T, Chang AH, Yan L, Xiong W.   +8 more
europepmc   +2 more sources

The Role of NKG2D in Vitiligo [PDF]

Frontiers in Immunology, 2021
Vitiligo is an acquired multifactorial disease that affects melanocytes and results in skin depigmentation. In this review, we examine the role of cells stress and self-reactive T cells responses. Given the canonical and non-canonical functions of NKG2D, such as authenticating stressed target and enhance TCR signaling, we examine how melanocyte stress ...
Lourdes Plaza-Rojas, José A. Guevara-Patiño   +1 more
openaire   +3 more sources

Harnessing Natural Killer Cells: From Neuroimmunology to Novel Therapies for Central Nervous System Diseases. [PDF]

MedComm (2020)
This review delineates the multifaceted roles of natural killer (NK) cells in the central nervous system, spanning direct cytolysis, immunoregulation, and crosstalk with the brain microenvironment. We evaluate the translational potential and challenges of NK cell immunotherapies for a spectrum of neurological conditions.
Deng K, Chong WP.
europepmc   +2 more sources

Leveraging NKG2D Ligands in Immuno-Oncology [PDF]

Frontiers in Immunology, 2021
Immune checkpoint inhibitors (ICI) revolutionized the field of immuno-oncology and opened new avenues towards the development of novel assets to achieve durable immune control of cancer. Yet, the presence of tumor immune evasion mechanisms represents a challenge for the development of efficient treatment options.
Mercedes Beatriz Fuertes, Carolina Inés Domaica, Norberto Walter Zwirner, Norberto Walter Zwirner   +3 more
openaire   +4 more sources

Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

Frontiers in Immunology, 2020
CAR T cell approaches to effectively target AML and T-ALL without off-tumor effects on healthy myeloid or T cell compartments respectively are an unmet medical need.
Lina Driouk, Joanina K. Gicobi, Yusuke Kamihara, Kayleigh Rutherford, Glenn Dranoff, Jerome Ritz, Jerome Ritz, Susanne H. C. Baumeister, Susanne H. C. Baumeister, Susanne H. C. Baumeister, Susanne H. C. Baumeister   +10 more
doaj   +1 more source

Acute myeloid leukemia and NK cells: two warriors confront each other

OncoImmunology, 2019
Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed ...
Aroa Baragaño Raneros, Carlos López-Larrea, Beatriz Suárez-Álvarez   +2 more
doaj   +1 more source

Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy

OncoImmunology, 2017
The use of high-dose interleukin-2 (IL-2) has fallen out of favor due to severe life-threatening side effects. We have recently described a unique way of directly targeting IL-2 to cytotoxic lymphocytes using a virally encoded immune evasion protein and ...
Eric Lazear, Reza Ghasemi, Sarah M. Hein, John Westwick, Dan Watkins, Daved H. Fremont, Alexander Sasha Krupnick   +6 more
doaj   +1 more source

NKG2D Ligands Expression and NKG2D-Mediated NK Activity in Sezary Patients [PDF]

Journal of Investigative Dermatology, 2009
Sezary syndrome (SS) is a rare lymphoma characterized by the clonal expansion in the skin and in blood of CD4(+)CD158k(+) T cells. Natural killer (NK) activation against tumors in leukemia models is partly based on the recognition of the target through the NKG2D/NKG2D ligands interactions. We analyzed ex vivo SS malignant lymphocytes for the expression
Dulphy, Nicolas, Berrou, Jeannig, Campillo, José A., Bagot, Martine, Bensussan, Armand, Toubert, Antoine   +5 more
openaire   +2 more sources

In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment

OncoImmunology, 2017
Despite aggressive treatment regimens based on surgery and radiochemotherapy, the prognosis of patients with grade IV glioblastoma multiforme (GBM) remains extremely poor, calling for alternative options such as immunotherapy.
Guranda Chitadze, Charlotte Flüh, Elgar Susanne Quabius, Sandra Freitag-Wolf, Christian Peters, Marcus Lettau, Jaydeep Bhat, Daniela Wesch, Hans-Heinrich Oberg, Stefanie Luecke, Ottmar Janssen, Michael Synowitz, Janka Held-Feindt, Dieter Kabelitz   +13 more
doaj   +1 more source